Julian Symons
Förmögenhet: 197 681 $ per 2026-09-30
Förmögenhet: 197 681 $ per 2026-09-30
Julian A. Symons is Chief Scientific Officer & Executive VP at Aligos Therapeutics, Inc. since 2018.
Formerly, Dr. Symons was Vice President-Disease Area Research & Development at Alios BioPharma, Inc. from 2015 to 2018.
Education includes a doctorate from York University and an undergraduate degree from the University of Central Lancashire.
| Företag | Datum | Antal aktier | Värdering | Värderingsdatum |
|---|---|---|---|---|
| 2026-03-31 | 35 112 ( 0,64 % ) | 197 681 $ | 2026-09-30 |
| Företag | Position | Start |
|---|---|---|
| ALIGOS THERAPEUTICS, INC. | Teknisk/Vetenskaplig/F&U Direktör | 2018-05-01 |
| Företag | Position | Slut |
|---|---|---|
Alios BioPharma, Inc.
Alios BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical stage biopharmaceutical company which develops novel antiviral therapies for the treatment of respiratory diseases | Företagsledare/Principal | 2018-04-01 |
Aktiva
Inaktiva
Börsnoterade företag
Privata företag
Första gradens relationer
Företag kopplade till första graden
Man
Kvinna
Styrelseledamöter
Chefer
| Privata företag | 4 |
|---|---|
Alios BioPharma, Inc.
Alios BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical stage biopharmaceutical company which develops novel antiviral therapies for the treatment of respiratory diseases | Health Technology |
York University
York University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Central Lancashire
University of Central Lancashire Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Aligos Therapeutics, Inc.
Aligos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops targeted, curative therapies for hepatologic diseases and viral infections | Health Technology |
Välj din utgåva
All finansiell information anpassad till den nationella nivån